Wertpapierdatensatz · archiviertes Quartal
AKRO
Akero Therapeutics, Inc. · Healthcare · Biotechnology
13Erfasste Halter
+1Δ Inhaber
19.73MGehaltene Aktien
$798.59MGemeldeter Wert
+1Neue Positionen
−0Ausstiege
Momentum-Eingaben (vergleichbare Manager):
Halterbreite +8.3% ·
Aktienfluss +7.6% ·
neue Nettopositionen +7.7%
— Formel
Breite Akkumulation — steigende Anteile bei mehr Haltern
Alle Eigentumszahlen: nur beobachtete 13F-Manager, Stammaktienpositionen, Berichtszeitraum Q1 2025
Beteiligung im Zeitverlauf
| Quartal | Inhaber | Δ | Aktien | Gemeldeter Wert | Neu | Ausstiege |
|---|---|---|---|---|---|---|
| Q3 2025 | 18 | 0 | 30.14M | $1.43B | +1 | −1 |
| Q2 2025 | 15 | -1 | 29.65M | $1.58B | — | −1 |
| Q1 2025 | 13 | +1 | 19.73M | $798.59M | +1 | — |
| Q4 2024 | 12 | +3 | 18.33M | $510.05M | +3 | — |
| Q3 2024 | 8 | 0 | 15.01M | $430.62M | +1 | −1 |
| Q2 2024 | 8 | — | 11.90M | $279.29M | — | — |
Wer es hält · Q1 2025
| # | Manager | Aktien | Δ Anteile | Wert | Deren Gewichtung | Gehalten | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 5.94M | -19.5% | $240.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 4.82M | +11.5% | $195.00M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 4.82M | +11.5% | $195.00M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | State Street Global Advisors ✦ (passiv) | 2.49M | +6.8% | $100.99M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 1.91M | +40.9% | $77.29M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 1.91M | +40.9% | $77.29M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 14 | Geode Capital Management ✦ (passiv) | 1.75M | +12.2% | $70.82M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Geode Capital Management ✦ (passiv) | 1.75M | +12.2% | $70.82M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | Marshall Wace ✦ | 1.61M | +484.5% | $65.09M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 17 | Marshall Wace ✦ | 1.61M | +484.5% | $65.09M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 18 | Point72 Asset Management ✦ | 508.34K | -43.5% | $20.58M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 19 | Millennium Management ✦ | 230.86K | +1279.5% | $9.35M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 20 | Renaissance Technologies ✦ | 199.00K | +856.7% | $8.06M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 21 | Adage Capital Partners ✦ | 195.00K | Neu | $7.89M | 0.0% | New | 1 | SEC ↗ |
| 22 | Two Sigma Investments ✦ | 62.02K | -51.3% | $2.51M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 12.16K | -66.0% | $492,196 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 5.76K | -33.4% | $233,286 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 5.76K | -33.4% | $233,286 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 5.76K | -33.4% | $233,286 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 5.76K | -33.4% | $233,286 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 5.76K | -33.4% | $233,286 | 0.0% | ▼ Trim | 2 | SEC ↗ |
„Ihre Gewichtung" = Anteil der Position am gemeldeten 13F-Eigenkapitalwert des jeweiligen Managers — das Conviction-Maß. ✦ = kuratorisch ausgewählter Manager.
Neue Käufer
| Adage Capital Partners | $7.89M | 0.0% |
Ausgestiegen
| Keine erfassten Ausstiege in diesem Quartal. |
Häufig gemeinsam gehalten
Was die erfassten Halter dieses Wertpapiers am häufigsten sonst noch halten — Zählungen gemeinsamer Eigentümerschaft, keine fundamentalen Zusammenhänge.
Herkunft: Beteiligung aus geparsten 13F-Common-Stock-Positionen (verfolgte Grundgesamtheit, vergleichbare Sets für Veränderungen); Insider-Zeilen aus Formularen 3/4/5; Beteiligungen aus Schedules 13D/13G; jede Einreichung verlinkt auf das Original auf SEC EDGAR.
Berichtszeitraum: Q1 2025 ·
Methodik ·
Über die API abrufen